bpc 157 tight junction intestinal barrier study BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Regulation of Tight Junction Permeability
Description
Gut and Liver , 2019
[2] However, once stores are depleted, symptoms can include fatigue, weakness, constipation, loss of appetite, and neurological changes such as numbness, tingling, balance problems, and cognitive difficulties
Support Care Cancer 30 , 45734575 (2022)
These include TNF-alpha, IL-1 beta, and IL-6, all of which drive joint destruction in inflammatory arthritis
